{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:11:54Z","timestamp":1773202314729,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Otsuka\/Lundbeck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40801-020-00178-8","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T06:02:42Z","timestamp":1580882562000},"page":"75-83","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9821-7958","authenticated-orcid":false,"given":"Nestor","family":"Szerman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9898-4105","authenticated-orcid":false,"given":"Ignacio","family":"Basurte-Villamor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-8602","authenticated-orcid":false,"given":"Pablo","family":"Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2856-6562","authenticated-orcid":false,"given":"Jose","family":"Martinez-Raga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Parro-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7381-2136","authenticated-orcid":false,"given":"Julia","family":"Cambra Almerge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1297-1819","authenticated-orcid":false,"given":"Lara","family":"Grau-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-9150","authenticated-orcid":false,"given":"Mario","family":"De Matteis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0740-9282","authenticated-orcid":false,"given":"Francisco","family":"Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"178_CR1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","volume":"191","author":"GE Hunt","year":"2018","unstructured":"Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234\u201358.","journal-title":"Drug Alcohol Depend"},{"key":"178_CR2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.schres.2005.02.010","volume":"76","author":"J de Leon","year":"2005","unstructured":"de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76:135\u201357.","journal-title":"Schizophr Res"},{"key":"178_CR3","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4088\/JCP.m04359","volume":"70","author":"RA Desai","year":"2009","unstructured":"Desai RA, Potenza MN. A cross-sectional study of problem and pathological gambling in patients with schizophrenia\/schizoaffective disorder. J Clin Psychiatry. 2009;70:1250\u20137.","journal-title":"J Clin Psychiatry"},{"key":"178_CR4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1176\/ajp.152.6.856","volume":"152","author":"TW Haywood","year":"1995","unstructured":"Haywood TW, Kravitz HM, Grossman LS, Cavanaugh JL, Davis JM, Lewis DA. Predicting the \u201crevolving door\u201d phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry. 1995;152:856\u201361.","journal-title":"Am J Psychiatry"},{"key":"178_CR5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1176\/ajp.155.2.226","volume":"155","author":"MS Swartz","year":"1998","unstructured":"Swartz MS, Swanson JW, Hiday VA, Borum R, Wagner HR, Burns BJ. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am J Psychiatry. 1998;155:226\u201331.","journal-title":"Am J Psychiatry"},{"key":"178_CR6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1017\/S003329170500574X","volume":"36","author":"S Potvin","year":"2006","unstructured":"Potvin S, Sepehry AA, Stip E. A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychol Med. 2006;36:431\u201340.","journal-title":"Psychol Med"},{"key":"178_CR7","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1080\/00048670701579041","volume":"41","author":"S Potvin","year":"2007","unstructured":"Potvin S, Sepehry AA, Stip E. Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. Aust N Z J Psychiatry. 2007;41:792\u20139.","journal-title":"Aust N Z J Psychiatry"},{"key":"178_CR8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.schres.2009.06.010","volume":"113","author":"S Potvin","year":"2009","unstructured":"Potvin S, Blanchet P, Stip E. Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophr Res. 2009;113:181\u20138.","journal-title":"Schizophr Res"},{"key":"178_CR9","doi-asserted-by":"crossref","first-page":"d738","DOI":"10.1136\/bmj.d738","volume":"342","author":"R Kuepper","year":"2011","unstructured":"Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10\u00a0year follow-up cohort study. BMJ. 2011;342:d738.","journal-title":"BMJ"},{"key":"178_CR10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.schres.2011.04.011","volume":"130","author":"LM Schmidt","year":"2011","unstructured":"Schmidt LM, Hesse M, Lykke J. The impact of substance use disorders on the course of schizophrenia\u2013a 15-year follow-up study: dual diagnosis over 15 years. Schizophr Res. 2011;130:228\u201333.","journal-title":"Schizophr Res"},{"key":"178_CR11","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1017\/S0033291717000046","volume":"47","author":"E Foglia","year":"2017","unstructured":"Foglia E, Schoeler T, Klamerus E, Morgan K, Bhattacharyya S. Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis. Psychol Med. 2017;47:1691\u2013705.","journal-title":"Psychol Med"},{"key":"178_CR12","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/0706743717720196","volume":"62","author":"D Crockford","year":"2017","unstructured":"Crockford D, Addington D. Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders. Can J Psychiatry. 2017;62:624\u201334.","journal-title":"Can J Psychiatry"},{"key":"178_CR13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/15622975.2015.1009163","volume":"16","author":"A Hasan","year":"2015","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenth\u00f8j B, Gattaz WF, Thibaut F, M\u00f6ller HJ, WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: update 2015 Management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015;16:142\u201370.","journal-title":"World J Biol Psychiatry."},{"key":"178_CR14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/BF02246063","volume":"119","author":"JP McEvoy","year":"1995","unstructured":"McEvoy JP, Freudenreich O, Levin ED, Rose JE. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology. 1995;119:124\u20136.","journal-title":"Psychopharmacology"},{"key":"178_CR15","first-page":"2635","volume":"11","author":"G Di Sciascio","year":"2015","unstructured":"Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015;11:2635\u201347.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"178_CR16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/187152710790966731","volume":"9","author":"DE Vergne","year":"2010","unstructured":"Vergne DE, Anton RF. Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS Neurol Disord: Drug Targets. 2010;9:50\u20134.","journal-title":"CNS Neurol Disord: Drug Targets"},{"key":"178_CR17","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00228-018-2498-1","volume":"74","author":"ELA Ribeiro","year":"2018","unstructured":"Ribeiro ELA, de Mendonca LT, Vieira MEB, Storpirtis S, Aguiar PM. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018;74:1215\u201333.","journal-title":"Eur J Clin Pharmacol"},{"key":"178_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/jcp.0b013e3181602fd4","volume":"28","author":"RF Anton","year":"2008","unstructured":"Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008;28:5\u201312.","journal-title":"J Clin Psychopharmacol"},{"key":"178_CR19","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/j.1530-0277.2008.00783.x","volume":"32","author":"K Voronin","year":"2008","unstructured":"Voronin K, Randall P, Myrick H, Anton R. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm\u2013possible influence of self-control. Alcohol Clin Exp Res. 2008;32:1954\u201361.","journal-title":"Alcohol Clin Exp Res"},{"key":"178_CR20","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.2174\/138161211796150783","volume":"17","author":"M Meini","year":"2011","unstructured":"Meini M, Moncini M, Cecconi D, Cellesi V, Biasci L, Simoni G, Ameglio M, Pellegrini M, Forgione RN, Rucci P. Aripiprazole and ropinirole treatment for cocaine dependence: evidence from a pilot study. Curr Pharm Des. 2011;17:1376\u201383.","journal-title":"Curr Pharm Des"},{"key":"178_CR21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/FBP.0000000000000268","volume":"28","author":"LM Moran","year":"2017","unstructured":"Moran LM, Phillips KA, Kowalczyk WJ, Ghitza UE, Agage DA, Epstein DH, Preston KL. Aripiprazole for cocaine abstinence: a randomized-controlled trial with ecological momentary assessment. Behav Pharmacol. 2017;28:63\u201373.","journal-title":"Behav Pharmacol"},{"key":"178_CR22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1037\/a0035165","volume":"22","author":"MR Lofwall","year":"2014","unstructured":"Lofwall MR, Nuzzo PA, Campbell C, Walsh SL. Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans. Exp Clin Psychopharmacol. 2014;22:238\u201347.","journal-title":"Exp Clin Psychopharmacol."},{"key":"178_CR23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/00952990802308262","volume":"34","author":"JA Lile","year":"2008","unstructured":"Lile JA, Stoops WW, Hays LR, Rush CR. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period. Am J Drug Alcohol Abuse. 2008;34:721\u20139.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"178_CR24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00213-011-2231-6","volume":"216","author":"M Haney","year":"2011","unstructured":"Haney M, Rubin E, Foltin RW. Aripiprazole maintenance increases smoked cocaine self-administration in humans. Psychopharmacology. 2011;216:379\u201387.","journal-title":"Psychopharmacology"},{"key":"178_CR25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/alcalc\/agx108","volume":"53","author":"CL Haass-Koffler","year":"2018","unstructured":"Haass-Koffler CL, Goodyear K, Zywiak WH, Leggio L, Kenna GA, Swift RM. Comparing and combining topiramate and aripiprazole on alcohol-related outcomes in a human laboratory study. Alcohol Alcohol. 2018;53:268\u201376.","journal-title":"Alcohol Alcohol"},{"key":"178_CR26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/0269881112472563","volume":"27","author":"DH Han","year":"2013","unstructured":"Han DH, Kim SM, Choi JE, Min KJ, Renshaw PF. Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence. J Psychopharmacol. 2013;27:282\u201391.","journal-title":"J Psychopharmacol."},{"key":"178_CR27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/JCP.0000000000000789","volume":"37","author":"T Beresford","year":"2017","unstructured":"Beresford T, Buchanan J, Thumm EB, Emrick C, Weitzenkamp D, Ronan PJ. Late reduction of cocaine cravings in a randomized, double-blind trial of aripiprazole vs perphenazine in schizophrenia and comorbid cocaine dependence. J Clin Psychopharmacol. 2017;37:657\u201363.","journal-title":"J Clin Psychopharmacol"},{"key":"178_CR28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0269881115612237","volume":"30","author":"RP Wilson","year":"2016","unstructured":"Wilson RP, Bhattacharyya S. Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: a systematic review. J Psychopharmacol. 2016;30:99\u2013111.","journal-title":"J Psychopharmacol."},{"key":"178_CR29","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/NDT.S171002","volume":"14","author":"I Cuomo","year":"2018","unstructured":"Cuomo I, Kotzalidis GD, de Persis S, Piacentino D, Perrini F, Amici E, De Filippis S. Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life. Neuropsychiatr Dis Treat. 2018;14:1645\u201356.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"178_CR30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1017\/S1092852919000117","volume":"24","author":"DH Huerta","year":"2019","unstructured":"Huerta DH, Sanchez EBA, Garcia CAC, Viorreta RT. 17 D2 receptor partial agonists in dual disorders: use of aripiprazole in psychotic disorder and comorbid substance use disorder. CNS Spectr. 2019;24:181\u20132.","journal-title":"CNS Spectr"},{"key":"178_CR31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","volume":"107","author":"JM Haro","year":"2003","unstructured":"Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, Rodriguez MJ, Rele R, Orta J, Kharbeng A, Araya S, Gervin M, Alonso J, Mavreas V, Lavrentzou E, Liontos N, Gregor K, Jones PB. The clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;107:16\u201323.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"178_CR32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12991-015-0042-6","volume":"14","author":"F Pinna","year":"2015","unstructured":"Pinna F, Deriu L, Diana E, Perra V, Randaccio RP, Sanna L, Tusconi M, Carpiniello B. Clinical global impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders. Ann Gen Psychiatry. 2015;14:6.","journal-title":"Ann Gen Psychiatry"},{"key":"178_CR33","volume-title":"Measuring health and disability: manual for who disability assessment schedule WHODAS 2.0","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. Measuring health and disability: manual for who disability assessment schedule WHODAS 2.0. Geneva: WHO Press; 2010."},{"key":"178_CR34","first-page":"77","volume":"28","author":"JL Vazquez-Barquero","year":"2000","unstructured":"Vazquez-Barquero JL, Bourgon EV, Castanedo SH, Saiz J, Uriarte M, Morales F, Gaite L, Herran A, Ustun TB. Spanish version of the new World Health Organization Disability Assessment Schedule II (WHO-DAS-II): initial phase of development and pilot study. Cantabria disability work group. Actas Esp Psiquiatr. 2000;28:77\u201387.","journal-title":"Actas Esp Psiquiatr."},{"key":"178_CR35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1360-0443.1995.9056072.x","volume":"90","author":"M Gossop","year":"1995","unstructured":"Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, Strang J. The severity of dependence scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995;90:607\u201314.","journal-title":"Addiction"},{"key":"178_CR36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0025-7753(08)75509-X","volume":"131","author":"F Gonzalez-Saiz","year":"2008","unstructured":"Gonzalez-Saiz F, de Las CC, Barrio G, Domingo-Salvany A. Spanish version of the severity of dependence scale (SDS). Med Clin (Barc). 2008;131:797\u20138.","journal-title":"Med Clin (Barc)."},{"key":"178_CR37","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/10826080701801543","volume":"43","author":"F Gonzalez-Saiz","year":"2008","unstructured":"Gonzalez-Saiz F, Lozano OM, Ballesta R, Silva T, Brugal MT, Bilbao I, Barrio G, Domingo-Salvany A, Bravo MJ, De la Fuente L, Del Proyecto IG. Validity of the Severity of Dependence Scale (SDS) construct applying the item response theory to a non-clinical sample of heroin users. Subst Use Misuse. 2008;43:919\u201335.","journal-title":"Subst Use Misuse"},{"key":"178_CR38","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.4088\/JCP.13m08838","volume":"76","author":"AI Green","year":"2015","unstructured":"Green AI, Brunette MF, Dawson R, Buckley P, Wallace AE, Hafez H, Herz M, Narasimhan M, Noordsy DL, O\u2019Keefe C, Sommi RW, Steinbook RM, Weeks M. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J Clin Psychiatry. 2015;76:1359\u201365.","journal-title":"J Clin Psychiatry"},{"key":"178_CR39","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/070674370605100808","volume":"51","author":"G Rubio","year":"2006","unstructured":"Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry. 2006;51:531\u20139.","journal-title":"Can J Psychiatry"},{"key":"178_CR40","first-page":"179","volume":"20","author":"M Meini","year":"2011","unstructured":"Meini M, Moncini M, Cecconi D, Cellesi V, Biasci L, Simoni G, Ameglio M, Pellegrini M, Forgione RN, Rucci P. Safety, tolerability, and self-rated effects of aripiprazole and ropinirole treatment for cocaine dependence: a pilot study. Am J Addict. 2011;20:179\u201380.","journal-title":"Am J Addict"},{"key":"178_CR41","first-page":"CD006306","volume":"3","author":"BI Indave","year":"2016","unstructured":"Indave BI, Minozzi S, Pani PP, Amato L. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev. 2016;3:CD006306.","journal-title":"Cochrane Database Syst Rev."},{"key":"178_CR42","doi-asserted-by":"crossref","first-page":"e1169","DOI":"10.4088\/JCP.13r08525","volume":"74","author":"T Kishi","year":"2013","unstructured":"Kishi T, Matsuda Y, Iwata N, Correll CU. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2013;74:e1169\u201380.","journal-title":"J Clin Psychiatry"},{"key":"178_CR43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2174\/1570159X11311050003","volume":"11","author":"P Sabioni","year":"2013","unstructured":"Sabioni P, Ramos AC, Galduroz JC. The effectiveness of treatments for cocaine dependence in schizophrenic patients: a systematic review. Curr Neuropharmacol. 2013;11:484\u201390.","journal-title":"Curr Neuropharmacol"},{"key":"178_CR44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/0269881108089596","volume":"23","author":"G Martinotti","year":"2009","unstructured":"Martinotti G, Di Nicola M, Di Giannantonio M, Janiri L. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. J Psychopharmacol. 2009;23:123\u20139.","journal-title":"J Psychopharmacol."},{"key":"178_CR45","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/13543784.2016.1175431","volume":"25","author":"G Martinotti","year":"2016","unstructured":"Martinotti G, Orsolini L, Fornaro M, Vecchiotti R, De Berardis D, Iasevoli F, Torrens M, Di Giannantonio M. Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. Expert Opin Investig Drugs. 2016;25:719\u201328.","journal-title":"Expert Opin Investig Drugs"},{"key":"178_CR46","doi-asserted-by":"crossref","first-page":"e642","DOI":"10.4088\/JCP.12r08178","volume":"74","author":"T Kishi","year":"2013","unstructured":"Kishi T, Sevy S, Chekuri R, Correll CU. Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. J Clin Psychiatry. 2013;74:e642\u201354.","journal-title":"J Clin Psychiatry"},{"key":"178_CR47","unstructured":"Food and Drug Administration. FDA drug safety communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (abilify, abilify maintena, aristada). 2016. https:\/\/www.fda.gov\/drugs\/drugsafety\/ucm498662.htm. Accessed 15 April 2019."},{"key":"178_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby185","author":"AE Whitton","year":"2019","unstructured":"Whitton AE, Green AI, Pizzagalli DA, Roth RM, Williams JM, Brunette MF. Potent dopamine D2 antagonists block the reward-enhancing effects of nicotine in smokers with schizophrenia. Schizophr Bull. 2019. https:\/\/doi.org\/10.1093\/schbul\/sby185.","journal-title":"Schizophr Bull"},{"key":"178_CR49","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/JCP.0000000000000634","volume":"37","author":"M Etminan","year":"2017","unstructured":"Etminan M, Sodhi M, Samii A, Procyshyn RM, Guo M, Carleton BC. Risk of gambling disorder and impulse control disorder with aripiprazole, pramipexole, and ropinirole: a pharmacoepidemiologic study. J Clin Psychopharmacol. 2017;37:102\u20134.","journal-title":"J Clin Psychopharmacol"},{"key":"178_CR50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JCP.0000000000000444","volume":"36","author":"M Grall-Bronnec","year":"2016","unstructured":"Grall-Bronnec M, Sauvaget A, Perrouin F, Leboucher J, Etcheverrigaray F, Challet-Bouju G, Gaboriau L, Derkinderen P, Jolliet P, Victorri-Vigneau C. Pathological gambling associated with aripiprazole or dopamine replacement therapy: do patients share the same features? A review. J Clin Psychopharmacol. 2016;36:63\u201370.","journal-title":"J Clin Psychopharmacol"},{"key":"178_CR51","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fpsyt.2018.00575","volume":"9","author":"M Clerici","year":"2018","unstructured":"Clerici M, de Bartolomeis A, De Filippis S, Ducci G, Maremmani I, Martinotti G, Schifano F. Patterns of management of patients with dual disorder (psychosis) in Italy: a survey of psychiatrists and other physicians focusing on clinical practice. Front Psychiatry. 2018;9:575.","journal-title":"Front Psychiatry"},{"key":"178_CR52","doi-asserted-by":"crossref","first-page":"e0201371","DOI":"10.1371\/journal.pone.0201371","volume":"13","author":"G Ostuzzi","year":"2018","unstructured":"Ostuzzi G, Mazzi MA, Terlizzi S, Bertolini F, Aguglia A, Bartoli F, Bortolaso P, Callegari C, Caroleo M, Carr\u00e0 G, Corbo M, D\u2019Agostino A, Gastaldon C, Lucii C, Magliocco F, Martinotti G, Nos\u00e9 M, Ostinelli EG, Papola D, Piccinelli MP, Piccoli A, Purgato M, Tabacchi T, Turrini G, Ruggeri M, Barbui C, STAR Network Investigators. Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. PLoS One. 2018;13:e0201371.","journal-title":"PLoS One."},{"key":"178_CR53","first-page":"17","volume":"49","author":"N Poloni","year":"2019","unstructured":"Poloni N, Ielmini M, Caselli I, Lucca G, Gasparini A, Gasparini A, Lorenzoli G, Callegari C. Oral antipsychotic versus long-acting injections antipsychotic in schizophrenia spectrum disorder: a mirror analysis in a real-world clinical setting. Psychopharmacol Bull. 2019;49:17\u201327.","journal-title":"Psychopharmacol Bull"},{"key":"178_CR54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40501-015-0038-5","volume":"2","author":"DJ McCann","year":"2015","unstructured":"McCann DJ, Ramey T, Skolnick P. Outcome measures in medication trials for substance use disorders. Curr Treat Options Psychiatry. 2015;2:113\u201321.","journal-title":"Curr Treat Options Psychiatry"}],"updated-by":[{"DOI":"10.1007\/s40801-020-00184-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000}}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-020-00178-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40801-020-00178-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-020-00178-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T02:09:06Z","timestamp":1722391746000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40801-020-00178-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["178"],"URL":"https:\/\/doi.org\/10.1007\/s40801-020-00178-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40801-020-00184-w","asserted-by":"object"}]},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,5]]},"assertion":[{"value":"5 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a large effect of the change from baseline in the CGI severity score, from 5.9 to 2.4 for LAI aripiprazole and from 5.7 to 2.6 for LAI risperidone [29].","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study was supported by an unrestricted educational grant from Otsuka\/Lundbeck to the Fundaci\u00f3n de Patolog\u00eda Dual (Madrid, Spain).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"NS has received speaker honorarium from Lundbeck, Shire, Exeltis, Rubio, Indivior, and Adamed: IB-V has received Speaker honorarium from Servier, Exeltis, and Lundbeck; PV has received speaker-travel honorarium from Gilead, MSD, Abbvie, and Rubi\u00f3. JM-R is advisory board member for Shire and has received speaker honorarium from Lundbeck, Janssen, and Shire; CP-T has received speaker honorarium from Janssen and Servier, and travel grants from Lundbeck and Qualigen; JCA has received travel grants from Lundbeck and Janssen; LG-L has received speaker honorarium from Janssen; MdM has received speaker-travel honorarium from Janssen, Qualigen, Lundbeck; FA declares no conflict of interest related with this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was revised and approved by the Ethics Committee of the Hospital General Universitario Gregorio Mara\u00f1\u00f3n (Madrid, Spain).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}